Your browser is no longer supported. Please, upgrade your browser.
Settings
SYRS Syros Pharmaceuticals, Inc. daily Stock Chart
SYRS [NASD]
Syros Pharmaceuticals, Inc.
Index- P/E- EPS (ttm)-1.86 Insider Own1.60% Shs Outstand26.30M Perf Week-7.52%
Market Cap530.47M Forward P/E- EPS next Y-2.99 Insider Trans- Shs Float21.26M Perf Month9.92%
Income-50.10M PEG- EPS next Q-0.53 Inst Own77.20% Short Float4.06% Perf Quarter19.77%
Sales1.40M P/S378.91 EPS this Y-165.30% Inst Trans15.50% Short Ratio8.60 Perf Half Y82.86%
Book/sh3.56 P/B5.67 EPS next Y-43.10% ROA-54.40% Target Price26.50 Perf Year81.71%
Cash/sh3.48 P/C5.80 EPS next 5Y- ROE-60.30% 52W Range10.22 - 24.38 Perf YTD65.87%
Dividend- P/FCF- EPS past 5Y- ROI-59.30% 52W High-20.82% Beta-
Dividend %- Quick Ratio13.30 Sales past 5Y- Gross Margin- 52W Low88.85% ATR1.66
Employees55 Current Ratio13.30 Sales Q/Q- Oper. Margin- RSI (14)43.63 Volatility7.65% 9.14%
OptionableNo Debt/Eq0.00 EPS Q/Q14.10% Profit Margin- Rel Volume1.40 Prev Close20.17
ShortableYes LT Debt/Eq0.00 EarningsAug 21 Payout- Avg Volume100.41K Price19.30
Recom2.00 SMA20-11.53% SMA501.03% SMA20028.49% Volume122,580 Change-4.31%
Aug-10-17Downgrade JMP Securities Mkt Outperform → Mkt Perform
Aug-21-17 09:20AM  Syros Pharma Wins Orphan Designation From FDA 24/7 Wall St.
08:01AM  Syros Receives FDA Orphan Drug Designation for SY-1425 for Treatment of AML Business Wire
Aug-10-17 08:01AM  Syros Pharmaceuticals to Present at 2017 Wedbush PacGrow Healthcare Conference Business Wire -7.84%
Aug-09-17 04:05PM  Syros Reports Second Quarter 2017 Financial Results and Highlights Accomplishments and Upcoming Milestones Business Wire
Jul-21-17 08:01AM  Syros Publishes Foundational Data Supporting Ongoing Phase 2 Clinical Trial of SY-1425 for Genomically Defined AML and MDS Patients Business Wire +5.29%
Jun-23-17 08:01AM  Syros Presents Data at EHA Supporting Potential of SY-1425, Its First-in-Class Selective RAR Agonist, in Genomically Defined AML and MDS Patients Business Wire
Jun-19-17 08:01AM  Syros Presents Discovery of Key Genes Controlling the Autoimmune Response in Lupus in Late-Breaking Oral Presentation at FOCIS Meeting Business Wire +5.63%
Jun-15-17 03:25PM  ETFs with exposure to Syros Pharmaceuticals, Inc. : June 15, 2017 Capital Cube
Jun-13-17 04:01PM  Syros to Participate in JMP Securities Life Sciences Conference Business Wire
08:24AM  Syros Pharmaceuticals, Inc. breached its 50 day moving average in a Bullish Manner : SYRS-US : June 13, 2017 Capital Cube
Jun-12-17 08:01AM  Syros Appoints Srinivas Akkaraju to Its Board of Directors Business Wire +9.86%
May-29-17 08:20AM  Syros Pharmaceuticals, Inc. breached its 50 day moving average in a Bearish Manner : SYRS-US : May 29, 2017 Capital Cube
May-18-17 08:01AM  Syros to Present on SY-1425 in Combination with Standard-of-Care and Targeted Therapies in Genomically Defined Subsets of AML and MDS Patients Business Wire
May-15-17 04:31PM  Syros Reports First Quarter 2017 Financial Results and Highlights Accomplishments and Upcoming Milestones Business Wire
08:01AM  Syros Announces First Patient Dosed in Phase 1 Clinical Trial of SY-1365, Its First-in-Class Selective CDK7 Inhibitor, in Patients with Advanced Solid Tumors Business Wire
May-11-17 07:36PM  Syros Pharmaceuticals, Inc. Value Analysis (NASDAQ:SYRS) : May 11, 2017 Capital Cube
May-09-17 08:52AM  Syros Pharmaceuticals, Inc. breached its 50 day moving average in a Bearish Manner : SYRS-US : May 9, 2017 Capital Cube
May-08-17 04:01PM  Syros Announces Late-Breaking Oral Presentation on its Research Identifying Key Genes that Control the Auto-immune Response in Lupus at FOCIS Meeting Business Wire
08:01AM  Syros Presents New Insights on Mechanism of Action of SY-1425, Its First-in-Class Selective RAR Agonist, in Oral Plenary Session at AACR Hematologic Malignancies Conference Business Wire
May-04-17 04:01PM  Syros Reveals Discovery of Novel Drug Targets for Triple Negative Breast Cancer Business Wire
May-01-17 08:01AM  Syros Participates in International Symposium to Support MDS Foundations Efforts to Raise Awareness of Novel Therapies in Development for MDS Business Wire
Apr-27-17 08:01AM  Syros to Present on Its Pioneering Approach to Identify Novel Drug Targets Linked to Genomically Defined Subsets of Patients at IMPAKT Breast Cancer Conference Business Wire
Apr-26-17 04:05PM  Syros Closes $35 Million Private Financing Business Wire
Apr-21-17 08:01AM  Syros Announces $35 Million Private Placement Business Wire
Apr-18-17 08:01AM  Syros to Present on SY-1425, Its First-in-Class Selective RAR Agonist, in Oral Plenary Session at AACR Hematologic Malignancies Conference Business Wire
Apr-10-17 08:01AM  Syros Announces FDA Acceptance of IND to Advance SY-1365, Its First-in-Class Selective CDK7 Inhibitor, into Phase 1 Clinical Trial in Patients with Advanced Solid Tumors Business Wire
Apr-04-17 08:01AM  Syros Presents Data at AACR Further Supporting Clinical Potential of SY-1425, Its First-in-Class Selective RAR Agonist, for Genomically Defined AML and MDS Patients Business Wire
08:01AM  Syros Presents Data at AACR Further Supporting Clinical Potential of SY-1425, Its First-in-Class Selective RAR Agonist, for Genomically Defined AML and MDS Patients
Apr-03-17 08:01AM  Syros Presents New Preclinical Data at AACR Showing Anti-Tumor Activity of SY-1365, Its First-in-Class Selective CDK7 Inhibitor, in Multiple Difficult-to-Treat Solid Tumors Business Wire
Mar-31-17 08:31AM  Can Syros Pharmaceuticals (SYRS) Run Higher on Strong Earnings Estimate Revisions? Zacks
08:31AM  Can Syros Pharmaceuticals (SYRS) Run Higher on Strong Earnings Estimate Revisions?
Mar-24-17 06:33AM  Can The Uptrend Continue for Syros Pharmaceuticals (SYRS)? Zacks
06:33AM  Can The Uptrend Continue for Syros Pharmaceuticals (SYRS)?
Mar-23-17 01:04PM  SYROS PHARMACEUTICALS, INC. Financials
08:51AM  Syros Pharmaceuticals Stock: 3 Reasons Why SYRS Is a Top Choice for Momentum Investors Zacks
08:51AM  Syros Pharmaceuticals Stock: 3 Reasons Why SYRS Is a Top Choice for Momentum Investors
Mar-21-17 09:55AM  Syros Pharmaceuticals, Inc. :SYRS-US: Earnings Analysis: 2016 By the Numbers : March 21, 2017 Capital Cube -8.67%
09:55AM  Syros Pharmaceuticals, Inc. :SYRS-US: Earnings Analysis: 2016 By the Numbers : March 21, 2017
Mar-20-17 08:01AM  Syros Reports Fourth Quarter and Full Year 2016 Financial Results and Highlights Key Accomplishments and Upcoming Milestones Business Wire
07:02AM  SYROS PHARMACEUTICALS, INC. Files SEC form 10-K, Annual Report
Mar-01-17 04:31PM  Syros to Present New Data on Lead Drug Candidates, SY-1425 and SY-1365, and CDK12/13 Inhibitor Program at Upcoming AACR Annual Meeting Business Wire
08:01AM  Syros Pharmaceuticals to Present at Upcoming Investor Conferences Business Wire
Feb-27-17 08:01AM  Syros Reports Discovery of Novel Genomics Based Approach to Stratifying Patients with Acute Myeloid Leukemia at Cold Spring Harbor Conference Business Wire
Feb-21-17 08:01AM  Syros Drug Discovery Research in Immuno-Oncology Highlighted at UCSD Moores Cancer Center Symposium Business Wire
Feb-09-17 04:01PM  Syros Announces Publication in Cell Highlighting Gene Control as Important and Rapidly Progressing Area of Research for Yielding New Medicines to Treat Cancer Business Wire
Feb-07-17 08:01AM  Syros Pharmaceuticals to Present at 2017 BIO CEO & Investor Conference Business Wire
Jan-30-17 08:39AM  SYROS PHARMACEUTICALS, INC. Files SEC form 8-K, Change in Directors or Principal Officers
08:01AM  Syros Appoints Industry Leader Peter Wirth as Chair of Its Board of Directors Business Wire
Jan-10-17 11:00AM  Syros to Present at the 35th Annual J.P. Morgan Healthcare Conference Business Wire
Jan-09-17 09:02AM  SYROS PHARMACEUTICALS, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Other Events, Financia -9.03%
08:35AM  Syros Pharmaceuticals Announces 2017 Strategic Priorities and Goals Business Wire
Jan-06-17 07:35AM  Syros Pharmaceuticals, Inc. breached its 50 day moving average in a Bullish Manner : SYRS-US : January 6, 2017 -6.31%
Dec-27-16 11:30AM  Syros Pharmaceuticals, Inc. Value Analysis (NASDAQ:SYRS) : December 27, 2016 -10.11%
Dec-26-16 08:02AM  Syros Pharmaceuticals, Inc. breached its 50 day moving average in a Bearish Manner : SYRS-US : December 26, 2016
Dec-15-16 08:15PM  Is Syros Pharmaceuticals Inc (SYRS) A Good Stock To Buy? at Insider Monkey
12:20AM  A new name and new fund will ensure Cambridge's Flagship 'feels like a startup' at bizjournals.com
12:01AM  Flagship Ventures Evolves Name To Flagship Pioneering PR Newswire
Dec-10-16 08:30AM  Syros Pharmaceuticals Presents New Preclinical Data Demonstrating Significant Anti-Proliferative Effects of its First-in-Class Selective RAR Agonist in Genomically Defined Subsets of Breast Cancer Business Wire
Dec-05-16 08:01AM  Syros Pharmaceuticals Presents Data at ASH Annual Meeting Further Supporting Clinical Potential of Its First-in-Class Selective RAR Agonist for Genomically Defined Subsets of AML and MDS Patients Business Wire
Nov-22-16 07:15AM  Syros Pharmaceuticals, Inc. breached its 50 day moving average in a Bullish Manner : SYRS-US : November 22, 2016
Nov-21-16 08:01AM  Syros Pharmaceuticals Announces Late-Breaking Presentation on SY-1425 at San Antonio Breast Cancer Symposium Business Wire +5.35%
Nov-18-16 08:51PM  [$$] Arch Venture Partners Raises $408M at The Wall Street Journal
Nov-14-16 08:23AM  Syros Pharmaceuticals reports 3Q loss
08:05AM  Syros Pharmaceuticals Reports Third Quarter 2016 Financial Results and Provides Business Update Business Wire
07:04AM  SYROS PHARMACEUTICALS, INC. Files SEC form 10-Q, Quarterly Report
Nov-08-16 08:05AM  Syros Pharmaceuticals to Participate in Upcoming Investor Conferences Business Wire
Nov-03-16 09:01AM  Syros Pharmaceuticals to Present New Data on SY-1425, Its First-in-Class Potent and Selective RAR Agonist, at the ASH Annual Meeting Business Wire
Nov-02-16 08:27AM  Syros Pharmaceuticals, Inc. breached its 50 day moving average in a Bearish Manner : SYRS-US : November 2, 2016 -11.21%
Oct-11-16 08:05AM  Syros Announces Approval of Investigational Device Exemption (IDE) for Blood Test to Identify Cancer Patients with Proprietary Biomarkers Business Wire
Sep-26-16 08:05AM  Syros Announces Appointment of Gerald E. Quirk as Chief Legal Officer Business Wire
Sep-22-16 08:05AM  Syros Announces First Patient Enrolled in Phase 2 Clinical Trial of SY-1425 in Genomically Defined Patients with Acute Myeloid Leukemia or Myelodysplastic Syndrome Business Wire
Sep-16-16 01:41PM  5 Stocks That Healthcare Fund Deerfield Management Was Buying in Q2 at Insider Monkey
Sep-07-16 08:00AM  Syros Pharmaceuticals to Participate in Morgan Stanley Global Healthcare Conference Business Wire
Aug-29-16 04:01PM  Syros Scientific Founders Publish on First Selective CDK12 and CDK13 Inhibitor as Promising Approach for Treatment of Cancer Business Wire
Aug-26-16 08:00AM  Syros Pharmaceuticals to Present at BioCentury NewsMakers Conference Business Wire
Aug-17-16 08:15AM  Syros Pharmaceuticals (SYRS) Jumps: Stock Moves Up 36.1%
Aug-15-16 08:52AM  SYROS PHARMACEUTICALS, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements a +5.76%
08:00AM  Syros Pharmaceuticals Reports Second Quarter 2016 Financial Results and Provides Business Update Business Wire
Aug-03-16 08:00AM  Syros Pharmaceuticals to Present at Wedbush PacGrow Healthcare Conference Business Wire
Jul-25-16 06:26AM  Coverage initiated on Syros Pharmaceuticals by Piper Jaffray, JMP Securities and Wedbush +7.51%
Jul-07-16 11:16AM  Syros Pharmaceuticals (SYRS): Deerfield Management Discloses Position at Insider Monkey
Jul-06-16 04:06PM  SYROS PHARMACEUTICALS, INC. Files SEC form 8-K, Amendments to Articles of Inc. or Bylaws; Change in Fiscal Year, Fina
04:01PM  Syros Pharmaceuticals Announces Closing of Initial Public Offering, Including Full Exercise of Option to Purchase Additional Shares Business Wire
Jul-03-16 09:47AM  5 Potential IPOs in Holiday-Shortened Week at 24/7 Wall St.
Jun-29-16 08:34PM  Syros Pharmaceuticals Announces Pricing of Initial Public Offering Business Wire
Jun-20-16 07:44AM  Syros Pharmaceuticals sets IPO price expectations at MarketWatch
Syros Pharmaceuticals, Inc., a biopharmaceutical company, focuses on developing medicines that control genes to transform the lives of patients with cancer, immune-mediated diseases, and other diseases. The company's gene control platform identifies gene control targets linked to genomically defined patient populations and drugging gene control targets; identifies potential new drug targets across a range of diseases; provides lens for diagnosing and segmenting patients, including those with complex/multi-factorial diseases; and allows users to advance a wave of medicines with the potential to influence multiple drivers of disease through a single target. Its pipeline includes SY-1425, a selective RARa agonist for genomically defined subsets of patients with relapsed or refractory acute myeloid leukemia and relapsed high-risk myelodysplastic syndrome; and SY-1365, a selective CDK7 inhibitor for acute leukemia. Syros Pharmaceuticals, Inc. was formerly known as LS22, Inc. Syros Pharmaceuticals, Inc. was founded in 2011 and is based in Cambridge, Massachusetts.